R. Caspi, Autoimmunity in the immune privileged eye: pathogenic and regulatory T cells, Immunologic Research, vol.237, issue.1-3, pp.41-50, 2008.
DOI : 10.4049/jimmunol.180.10.6751

R. R. Caspi, F. G. Roberge, C. C. Chan, B. Wiggert, G. J. Chader et al., NUSSENBLATT : A new model of autoimmune disease. Experimental autoimmune uveoretinitis induced in mice with two different retinal antigens, J Immunol, issue.5, pp.1401490-1495, 1988.

D. E. Borst, T. M. Redmond, J. E. Elser, M. A. Gonda, B. Wiggert et al., Interphotoreceptor retinoid-binding protein. Gene characterization, protein repeat structure, and its evolution, J Biol Chem, vol.264, issue.2, pp.1115-1123, 1989.

R. K. Agarwal and R. R. , CASPI : Rodent models of experimental autoimmune uveitis, Methods Mol Med, vol.102, pp.395-419, 2004.

R. R. Caspi, B. Sun, R. K. Agarwal, P. B. Silver, L. V. Rizzo et al., WILDER : T cell mechanisms in experimental autoimmune uveoretinitis : susceptibility is a function of the cytokine response profile, Eye (Lond), issue.2, pp.11209-212, 1997.

H. Xu, L. V. Rizzo, P. B. Silver, and R. R. , Uveitogenicity Is Associated with a Th1-like Lymphokine Profile: Cytokine-Dependent Modulation of Early and Committed Effector T Cells in Experimental Autoimmune Uveitis, Cellular Immunology, vol.178, issue.1, pp.69-78, 1997.
DOI : 10.1006/cimm.1997.1121

B. Sun, S. H. Sun, C. C. Chan, B. Wiggert, and R. R. Caspi, Autoimmunity to a pathogenic retinal antigen begins as a balanced cytokine response that polarizes towards type 1 in a disease-susceptible and towards type 2 in a disease-resistant genotype, International Immunology, vol.11, issue.8, pp.111307-1312, 1999.
DOI : 10.1002/eji.1830270623

L. S. Jones, L. V. Rizzo, R. K. Agarwal, T. K. Tarrant, C. C. Chan et al., CASPI : IFN-gamma-deficient mice develop experimental autoimmune uveitis in the context of a deviant effector response, J Immunol, issue.12, pp.1585997-6005, 1997.

S. B. Su, R. S. Grajewski, D. Luger, R. K. Agarwal, P. B. Silver et al., Altered chemokine profile associated with exacerbated autoimmune pathology under conditions of genetic interferon-gamma deficiency, Invest Ophthalmol Vis Sci, issue.10, pp.484616-4625, 2007.

K. Kikly, L. Liu, S. Na, and J. D. , The IL-23/Th17 axis: therapeutic targets for autoimmune inflammation, Current Opinion in Immunology, vol.18, issue.6, pp.670-675, 2006.
DOI : 10.1016/j.coi.2006.09.008

V. S. Costa, T. C. Mattana, M. E. Da, and S. , Unregulated IL-23/IL-17 immune response in autoimmune diseases, Diabetes Research and Clinical Practice, vol.88, issue.3, pp.222-226, 2010.
DOI : 10.1016/j.diabres.2010.03.014

J. C. Crispín and G. C. , Interleukin-17-producing T cells in lupus, Current Opinion in Rheumatology, vol.22, issue.5, pp.499-503, 2010.
DOI : 10.1097/BOR.0b013e32833c62b0

D. Luger, P. B. Silver, J. Tang, D. Cua, Z. Chen et al., Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category, The Journal of Experimental Medicine, vol.36, issue.4, pp.799-810, 2008.
DOI : 10.1016/0896-8411(90)90144-H

L. Wang, C. Yu, H. Kim, W. Liao, W. G. Telford et al., Key role for IL-21 in experimental autoimmune uveitis, Proceedings of the National Academy of Sciences, vol.101, issue.48, pp.9542-9547, 2011.
DOI : 10.1073/pnas.0407752101

D. Luger and R. R. , New perspectives on effector mechanisms in uveitis, Seminars in Immunopathology, vol.204, issue.2, pp.135-143, 2008.
DOI : 10.4049/jimmunol.172.11.7169

W. Chi, X. Zhu, P. Yang, X. Liu, X. Lin et al., Upregulated IL-23 and IL-17 in Behc??et Patients with Active Uveitis, Investigative Opthalmology & Visual Science, vol.49, issue.7, pp.3058-3064, 2008.
DOI : 10.1167/iovs.07-1390

S. Jiang, X. Liu, L. Luo, B. Qu, X. Huang et al., Elevated serum IL-23 correlates with intraocular inflammation after cataract surgery in patients with Vogt-Koyanagi-Harada disease, British Journal of Ophthalmology, vol.94, issue.8, pp.941078-1082, 2010.
DOI : 10.1136/bjo.2009.169052

J. J. Kuiper, T. Mutis, W. De, J. , J. D. De et al., Intraocular Interleukin-17 and Proinflammatory Cytokines in HLA-A29???Associated Birdshot Chorioretinopathy, American Journal of Ophthalmology, vol.152, issue.2, 2011.
DOI : 10.1016/j.ajo.2011.01.031

P. P. Sfikakis, P. G. Theodossiadis, C. G. Katsiari, P. Kaklamanis, and N. N. , MARKOMICHELAKIS : Effect of infliximab on sight-threatening panuveitis in Behçet's disease, Lancet, issue.9278, pp.358295-296, 2001.

M. C. Avunduk, A. M. Avunduk, E. Oztekin, A. K. Baltaci, Y. Ozyazgan et al., Etanercept treatment in the endotoxin-induced uveitis of rats

C. C. Murphy, K. Greiner, J. Plskova, L. Duncan, A. Frost et al., Neutralizing Tumor Necrosis Factor Activity Leads to Remission in PatientsWith Refractory Noninfectious Posterior Uveitis, Archives of Ophthalmology, vol.122, issue.6, pp.845-851, 2004.
DOI : 10.1001/archopht.122.6.845

W. , F. Mandelli, G. Saglio, M. Lazzarino, D. Russo et al., Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia, N Engl J Med, vol.346, issue.9, pp.645-652, 2002.

R. J. Motzer, T. E. Hutson, P. Tomczak, M. D. Michaelson, R. M. Bu-kowski et al., Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma, New England Journal of Medicine, vol.356, issue.2, pp.115-124, 2007.
DOI : 10.1056/NEJMoa065044

A. Heine, S. A. Held, A. Bringmann, T. A. Holderried, and P. Bros-sart, Immunomodulatory effects of anti-angiogenic drugs, Leukemia, vol.29, issue.6, pp.899-905, 2011.
DOI : 10.1038/nm1763

C. Louvet, G. L. Szot, J. Lang, M. R. Lee, N. Martinier et al., Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice, Proceedings of the National Academy of Sciences, vol.145, issue.2, pp.10518895-18900, 2008.
DOI : 10.1210/en.2003-1274

W. Ando, J. Hashimoto, A. Nampei, H. Tsuboi, K. Tateishi et al., Imatinib mesylate inhibits osteoclastogenesis and joint destruction in rats with collagen-induced arthritis (CIA), Journal of Bone and Mineral Metabolism, vol.43, issue.4, pp.274-282, 2006.
DOI : 10.4049/jimmunol.168.11.5824

K. K. Eklund, A. Remitz, H. Kautiainen, S. Reitamo, and M. Leirisalo-repo, Three months treatment of active spondyloarthritis with imatinib mesylate: an open-label pilot study with six patients, Rheumatology, vol.45, issue.12, pp.451573-1575, 2006.
DOI : 10.1093/rheumatology/kel365

K. Koyama, K. Hatsushika, T. Ando, M. Sakuma, M. Wako et al., Imatinib mesylate both prevents and treats the arthritis induced by type II collagen antibody in mice, Modern Rheumatology, vol.8, issue.4, pp.306-310, 2007.
DOI : 10.1002/1529-0131(200111)44:11<2512::AID-ART431>3.0.CO;2-O

G. , P. J. Utz, L. Steinman, and W. H. Robinson, Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis, J Clin Invest, vol.116, issue.10, pp.2633-2642, 2006.

A. B. Dietz, L. Souan, G. J. Knutson, P. A. Bulur, M. R. Litzow et al., Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo, Blood, vol.104, issue.4, pp.1094-1099, 2004.
DOI : 10.1182/blood-2003-12-4266

A. M. Wolf, D. Wolf, H. Rumpold, S. Ludwiczek, B. Enrich et al., The kinase inhibitor imatinib mesylate inhibits TNF-alpha production in vitro and prevents TNF-dependent acute hepatic inflammation, Proc Natl Acad Sci, issue.38, pp.10213622-13627, 2005.

E. Cabebe and H. Wakelee, Sunitinib: A newly approved small-molecule inhibitor of angiogenesis, Drugs of Today, vol.42, issue.6, pp.387-98, 1998.
DOI : 10.1358/dot.2006.42.6.985633

Y. Gu, W. Zhao, F. Meng, B. Qu, X. Zhu et al., Sunitinib impairs the proliferation and function of human peripheral T cell and prevents T-cellmediated immune response in mice, Clinical immunology, issue.1, pp.135-55, 2010.

M. Huang, X. Liu, Q. Du, X. Yao, K. Sheng et al., Inhibitory effects of sunitinib on ovalbumin-induced chronic experimental asthma in mice, Chin Med J (Engl), vol.122, issue.9, pp.1061-1066, 2009.

D. Mokhtari and N. Welsh, Potential utility of small tyrosine kinase inhibitors in the treatment of diabetes, Clinical Science, vol.115, issue.4, pp.241-248, 1979.
DOI : 10.1016/j.cellsig.2006.02.012

J. D. Luna, C. C. Chan, N. L. Derevjanik, J. Mahlow, C. Chiu et al., Blood-retinal barrier (BRB) breakdown in experimental autoimmune uveoretinitis: Comparison with vascular endothelial growth factor, tumor necrosis factor ?, and interleukin-1?-mediated breakdown, Journal of Neuroscience Research, vol.49, issue.3, pp.268-80, 1997.
DOI : 10.1002/(SICI)1097-4547(19970801)49:3<268::AID-JNR2>3.0.CO;2-A

J. L. Edelman, D. Lutz, and M. R. Castro, Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of blood???retinal and blood???aqueous barrier breakdown, Experimental Eye Research, vol.80, issue.2, pp.249-58, 2005.
DOI : 10.1016/j.exer.2004.09.013

N. Gulati, F. Forooghian, R. Lieberman, and D. A. , Vascular endothelial growth factor inhibition in uveitis: a systematic review, British Journal of Ophthalmology, vol.95, issue.2, pp.162-167, 2011.
DOI : 10.1136/bjo.2009.177279

M. Kamoun, M. H. Houman, and A. Hamzaoui, Vascular endothelial growth factor gene polymorphisms and serum levels in Beh??et???s disease, Tissue Antigens, vol.30, issue.6, pp.581-588, 2009.
DOI : 10.1042/cs0940395

S. Kase, K. Aoki, T. Harada, C. Harada, K. Ohgami et al., Activation of nuclear factor-kappa B in the conjunctiva with the epithelial scraping of the mouse cornea and human epidemic keratoconjunctivitis, British Journal of Ophthalmology, vol.88, issue.7, pp.88947-949, 2004.
DOI : 10.1136/bjo.2003.024646

S. Lee, J. Kim, Y. Park, and S. Lee, Bortezomib attenuates murine collagen-induced arthritis, Annals of the Rheumatic Diseases, vol.68, issue.11, pp.681761-681768, 2009.
DOI : 10.1136/ard.2008.097709

B. Blanco, J. A. Pérez-simón, L. I. Sánchez-abarca, X. Carvajal-vergara, J. Mateos et al., Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines, Blood, vol.107, issue.9, pp.3575-3583, 2006.
DOI : 10.1182/blood-2005-05-2118

Y. Yamamoto and R. B. Gaynor, Therapeutic potential of inhibition of the NF-??B pathway in the treatment of inflammation and cancer, Journal of Clinical Investigation, vol.107, issue.2, pp.135-142, 2001.
DOI : 10.1172/JCI11914

P. J. Elliott, T. M. Zollner, and W. Boehncke, Proteasome inhibition: a new anti-inflammatory strategy, Journal of Molecular Medicine, vol.6, issue.4, pp.235-245, 2003.
DOI : 10.1016/S1074-5521(99)80128-8

D. Iwata, N. Kitaichi, A. Miyazaki, K. Iwabuchi, K. Yoshida et al., Amelioration of Experimental Autoimmune Uveoretinitis with Nuclear Factor-??B Inhibitor Dehydroxy Methyl Epoxyquinomicin in Mice, Investigative Opthalmology & Visual Science, vol.51, issue.4, pp.2077-2084, 2010.
DOI : 10.1167/iovs.09-4030

N. A. Rao, Role of oxygen free radicals in retinal damage associated with experimental uveitis, Trans Am Ophthalmol Soc, vol.88, pp.797-850, 1990.

G. S. Wu, J. Zhang, and N. A. Rao, Peroxynitrite and oxidative damage in experimental autoimmune uveitis, Invest Ophthalmol Vis Sci, vol.38, issue.7, pp.1333-1339, 1997.

S. E. Ohia, C. A. Opere, and A. M. , Pharmacological consequences of oxidative stress in ocular tissues, Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, vol.579, issue.1-2, pp.22-36, 2005.
DOI : 10.1016/j.mrfmmm.2005.03.025

A. Isik, S. S. Koca, and B. Ustundag, Decreased Total Antioxidant Response and Increased Oxidative Stress in Behcet's Disease, The Tohoku Journal of Experimental Medicine, vol.212, issue.2, pp.133-141, 2007.
DOI : 10.1620/tjem.212.133

A. Templeton, M. Brändle, T. Cerny, and S. Gillessen, Remission of diabetes while on sunitinib treatment for renal cell carcinoma, Annals of Oncology, vol.19, issue.4, pp.824-825, 2008.
DOI : 10.1093/annonc/mdn047

N. Agostino, V. M. Chinchilli, C. J. Lynch, A. Koszyk-szewczyk, R. Gin-grich et al., DRABICK : Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice, J Oncol Pharm Pract, 2010.

J. A. Emamaullee, J. Davis, S. Merani, C. Toso, J. F. Elliott et al., Inhibition of Th17 Cells Regulates Autoimmune Diabetes in NOD Mice, Diabetes, vol.58, issue.6, pp.1302-1311, 2009.
DOI : 10.2337/db08-1113

E. M. Bradshaw, K. Raddassi, W. Elyaman, T. Orban, P. A. Gottlieb et al., Monocytes from Patients with Type 1 Diabetes Spontaneously Secrete Proinflammatory Cytokines Inducing Th17 Cells, The Journal of Immunology, vol.183, issue.7, pp.4432-4439, 2009.
DOI : 10.4049/jimmunol.0900576

J. Honkanen, J. K. Nieminen, R. Gao, K. Luopajarvi, H. M. Salo et al., IL-17 Immunity in Human Type 1 Diabetes, The Journal of Immunology, vol.185, issue.3, pp.1959-1967, 2010.
DOI : 10.4049/jimmunol.1000788

Y. Peng, G. Han, H. Shao, Y. Wang, H. J. Kaplan et al., Interphotoreceptor Retinoid-Binding Protein-Specific T Cells in Experimental Autoimmune Uveitis, Investigative Opthalmology & Visual Science, vol.48, issue.9, pp.4153-4161, 2007.
DOI : 10.1167/iovs.07-0251

X. Zhong, H. Huang, J. Shen, S. Zacchigna, L. Zentilin et al., VINORES : Vascular endothelial growth factor-B gene transfer exacerbates retinal and choroidal neovascularization and vasopermeability without promoting inflammation, Molecular vision, vol.17, pp.492-507, 2011.

J. Penn, A. Madan, R. Caldwell, M. Bartoli, R. Caldwell et al., Vascular endothelial growth factor in eye disease, Progress in Retinal and Eye Research, vol.27, issue.4, pp.331-371, 2008.
DOI : 10.1016/j.preteyeres.2008.05.001

A. B. El-remessy, M. A. Behzadian, G. Abou-mohamed, T. Franklin, R. W. Caldwell et al., Experimental Diabetes Causes Breakdown of the Blood-Retina Barrier by a Mechanism Involving Tyrosine Nitration and Increases in Expression of Vascular Endothelial Growth Factor and Urokinase Plasminogen Activator Receptor, The American Journal of Pathology, vol.162, issue.6, pp.1995-2004, 2003.
DOI : 10.1016/S0002-9440(10)64332-5

M. Cekmen, C. Evereklioglu, H. Er, H. S. Inaloz, S. Doganay et al., Vascular endothelial growth factor levels are increased and associated with disease activity in patients with Behcet's syndrome, International journal of dermatology, issue.11, pp.42870-42875, 2004.

H. F. Fine, J. Baffi, G. F. Reed, K. G. Csaky, and R. B. , Aqueous humor and plasma vascular endothelial growth factor in uveitis-associated cystoid macular edema, American Journal of Ophthalmology, vol.132, issue.5, pp.794-800, 2001.
DOI : 10.1016/S0002-9394(01)01103-5

J. C. Tille, J. Wood, S. J. Mandriota, C. Schnell, S. Ferrari et al., Vascular endothelial growth factor (vegf) receptor-2 antagonists inhibit vegf-and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro, J Pharmacol Exp Ther, issue.3, pp.2991073-1085, 2001.

J. H. Kim, J. H. Kim, Y. M. Lee, E. Ahn, K. Kim et al., Decursin Inhibits VEGF-Mediated Inner Blood???Retinal Barrier Breakdown by Suppression of VEGFR-2 Activation, Journal of Cerebral Blood Flow & Metabolism, vol.39, issue.9, pp.1559-67, 2009.
DOI : 10.1016/S0014-4835(05)80048-X

N. A. Rao, Role of oxygen free radicals in retinal damage associated with experimental uveitis, Trans Am Ophthalmol Soc, vol.88, pp.797-850, 1990.

D. J. Parks, M. K. Cheung, C. C. Chan, and F. G. Roberge, The Role of Nitric Oxide in Uveitis, Archives of Ophthalmology, vol.112, issue.4, pp.544-546, 1994.
DOI : 10.1001/archopht.1994.01090160124032

A. M. Joussen, V. Poulaki, W. Qin, B. Kirchhof, N. Mitsiades et al., Retinal Vascular Endothelial Growth Factor Induces Intercellular Adhesion Molecule-1 and Endothelial Nitric Oxide Synthase Expression and Initiates Early Diabetic Retinal Leukocyte Adhesion in Vivo, The American Journal of Pathology, vol.160, issue.2, pp.501-509, 2002.
DOI : 10.1016/S0002-9440(10)64869-9

J. H. Finke, B. Rini, J. Ireland, P. Rayman, A. Richmond et al., Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients, Clinical Cancer Research, vol.14, issue.20, pp.146674-6682, 2008.
DOI : 10.1158/1078-0432.CCR-07-5212

J. D. Katz and C. Benoist, T helper cell subsets in insulin-dependent diabetes, Science, vol.268, issue.5214, pp.1185-1188, 1995.
DOI : 10.1126/science.7761837

L. M. Bradley, V. C. Asensio, L. K. Schioetz, J. Harbertson, T. Krahl et al., SARVETNICK : Islet-specific Th1, but not Th2, cells secrete multiple chemokines and promote rapid induction of autoimmune diabetes, J Immunol, vol.162, issue.5, pp.2511-2520, 1999.

M. G. Karlsson, S. S. Lawesson, and J. Ludvigsson, Th1-like dominance in high-risk first-degree relatives of Type I diabetic patients, Diabetologia, vol.43, issue.6, pp.742-749, 2000.
DOI : 10.1007/s001250051372

S. Arif, T. I. Tree, T. P. Astill, J. M. Tremble, A. J. Bishop et al., Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health, Journal of Clinical Investigation, vol.113, issue.3, pp.451-463, 2004.
DOI : 10.1172/JCI19585

J. Hung, J. Liao, Y. Lin, H. Chang, S. Wu et al., Immunopathogenic role of TH1 cells in autoimmune diabetes: Evidence from a T1 and T2 doubly transgenic non-obese diabetic mouse model, Journal of Autoimmunity, vol.25, issue.3, pp.181-192, 2005.
DOI : 10.1016/j.jaut.2005.08.010

J. Cantor and K. Haskins, Effector Function of Diabetogenic CD4 Th1 T Cell Clones: A Central Role for TNF-??, The Journal of Immunology, vol.175, issue.11, pp.7738-7745, 2005.
DOI : 10.4049/jimmunol.175.11.7738

A. Chatzigeorgiou, V. Harokopos, C. Mylona-karagianni, E. Tsouva-las, V. Aidinis et al., The pattern of inflammatory/anti-inflammatory cytokines and chemokines in type 1 diabetic patients over time, Annals of Medicine, vol.76, issue.6, pp.426-438, 2010.
DOI : 10.1016/j.jbspin.2008.08.002

R. R. Caspi, Understanding Autoimmune Uveitis through Animal Models The Friedenwald Lecture, Investigative Opthalmology & Visual Science, vol.52, issue.3, pp.1872-1879, 2011.
DOI : 10.1167/iovs.10-6909

J. Kim, J. A. Park, E. Y. Lee, Y. J. Lee, Y. W. Song et al., LEE : Imbalance of Th17 to Th1 cells in Beh cet's disease, Clin Exp Rheumatol, vol.28, issue.4, pp.16-19, 2010.

M. M. Hipp, N. Hilf, S. Walter, D. Werth, K. M. Brauer et al., BROSSART : Sorafenib, but not sunitinib , affects function of dendritic cells and induction of primary immune responses, Blood, issue.12, pp.1115610-5620, 2008.

K. J. Gotink and H. M. , VERHEUL : Anti-angiogenic tyrosine kinase inhibitors : what is their mechanism of action ? Angiogenesis, pp.1-14